#407 Erkenningsnummer P708816
NOVEMBER 25, 2015 \ NEwswEEkly - € 0,75 \ rEad morE at www.flandErstoday.Eu currEnt affairs \ P2
Politics \ P4
BusinEss \ P6
innovation \ P7
art & living \ P10
alone TogeTher
Terror alerT level 4
Brussels in lockdown as security forces seek suspect in Paris attacks
Education \ P9
Flemish author Saskia De Coster’s new book looks at the isolation of modern life \ 13
\2
Better together
ghent university and Janssen Pharmaceutica join forces in search of medical breakthroughs senne starckx More articles by senne \ flanderstoday.eu
The days when academia and industry occupied different worlds are long past, and in medical research, an interplay between public and private is now the rule rather than the exception. A new partnership between Ghent University and Janssen Pharmaceutica aims to build on this connection to develop the medicines of tomorrow.
“T
oday is a beautiful day, as good friends and close neighbours now become true partners.” With those words last month, Anne De Paepe, rector of Ghent University (UGent), launched the new partnership between the university, the university hospital (UZ Gent) and Janssen Pharmaceutica, one of the biggest pharmaceutical companies in the world. De Paepe emphasised the informal nature in which the
worlds of academia and big pharma have converged in the past decade. “The projects in basic, translational and clinical research that this collaboration sparked were primarily established by personal interactions between researchers from my university and Janssen,” she said. With the new partnership, UGent aims to deliver a framework to help foster and reinforce that bottom-up collaboration and to explore new ones. “We will do this according to an open and innovative model,” said De Paepe, “with due respect to our autonomous academic identity and independence.” The days when medical research in academia and industry occupied two separate worlds are gone. Biological insights are changing and becoming ever more complex. To control disease or to promote good health, drug developers need a profound understanding of biology. And to that purpose, they
need to be at the frontier of scientific research. That’s exactly where academia and big pharma meet – “a meeting point where they can have a true impact on patients’ lives,” according to De Paepe. With this in mind, it’s not surprising that, over the years, interactions between academia and industry have increased in order to jointly explore these scientific frontiers through top-class, evidence-based research. Meanwhile, there’s a worldwide race in the life sciences going on. Whether Europe wins this race will depend on sustainable co-creation models in balanced public-private partnerships. A partnership means of course that both UGent and UZ Gent will collaborate more closely with Janssen, by exchanging knowledge and expertise, encouraging scientific talent and bringing medical innovations to patients more quickly. This continued on page 5